Skip to main content
Journal of Virology logoLink to Journal of Virology
. 1997 Nov;71(11):8195–8203. doi: 10.1128/jvi.71.11.8195-8203.1997

Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

H Pelemans 1, R Esnouf 1, A Dunkler 1, M A Parniak 1, A M Vandamme 1, A Karlsson 1, E De Clercq 1, J P Kleim 1, J Balzarini 1
PMCID: PMC192276  PMID: 9343170

Abstract

Treatment of human immunodeficiency virus type 1 (HIV-1)-infected CEM cell cultures with escalating concentrations of the quinoxaline S-2720 resulted in an ordered appearance of single and multiple mutant virus strains that gradually became resistant to the quinoxaline and other nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs). A novel mutation, Pro225His, consistently appeared in a Val106Ala RT-mutated genetic background. The contribution of this mutation to the resistance of the mutant HIV-1 RT to NNRTIs was additive to the resistance caused by the Val106Ala mutation. Interestingly, site-directed mutagenesis studies revealed that the Pro225His-mutated RT had acquired markedly greater sensitivity to bis(heteroaryl)piperazine (BHAP U-90152) (delavirdine) but not to any of the other NNRTIs. The kinetics of inhibition of the Pro225His mutant RT by the NNRTIs (including BHAP U-90152) was not substantially different from that observed for the wild-type RT. The hypersensitivity of the mutant enzyme and virus to BHAP U-90152 could be rationally explained by the molecular-structural determinants of the RT-BHAP complex, which has recently been resolved by X-ray crystallography.

Full Text

The Full Text of this article is available as a PDF (975.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balzarini J., Karlsson A., Meichsner C., Paessens A., Riess G., De Clercq E., Kleim J. P. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J Virol. 1994 Dec;68(12):7986–7992. doi: 10.1128/jvi.68.12.7986-7992.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balzarini J., Pérez-Pérez M. J., San-Félix A., Camarasa M. J., Bathurst I. C., Barr P. J., De Clercq E. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T). J Biol Chem. 1992 Jun 15;267(17):11831–11838. [PubMed] [Google Scholar]
  3. Camarasa M. J., Pérez-Pérez M. J., San-Félix A., Balzarini J., De Clercq E. 3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides. J Med Chem. 1992 Jul 24;35(15):2721–2727. doi: 10.1021/jm00093a002. [DOI] [PubMed] [Google Scholar]
  4. D'Aquila R. T., Summers W. C. HIV-1 reverse transcriptase/ribonuclease H: high level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction. J Acquir Immune Defic Syndr. 1989;2(6):579–587. [PubMed] [Google Scholar]
  5. De Clercq E What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections? Rev Med Virol. 1996 Jun;6(2):97–117. doi: 10.1002/(SICI)1099-1654(199606)6:2<97::AID-RMV168>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  6. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol. 1994 Jan 20;47(2):155–169. doi: 10.1016/0006-2952(94)90001-9. [DOI] [PubMed] [Google Scholar]
  7. Dueweke T. J., Pushkarskaya T., Poppe S. M., Swaney S. M., Zhao J. Q., Chen I. S., Stevenson M., Tarpley W. G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4713–4717. doi: 10.1073/pnas.90.10.4713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Esnouf R. M., Ren J., Hopkins A. L., Ross C. K., Jones E. Y., Stammers D. K., Stuart D. I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3984–3989. doi: 10.1073/pnas.94.8.3984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol. 1995 Apr;2(4):303–308. doi: 10.1038/nsb0495-303. [DOI] [PubMed] [Google Scholar]
  10. Fletcher R. S., Holleschak G., Nagy E., Arion D., Borkow G., Gu Z., Wainberg M. A., Parniak M. A. Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. Protein Expr Purif. 1996 Feb;7(1):27–32. doi: 10.1006/prep.1996.0004. [DOI] [PubMed] [Google Scholar]
  11. Gu Z., Gao Q., Li X., Parniak M. A., Wainberg M. A. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol. 1992 Dec;66(12):7128–7135. doi: 10.1128/jvi.66.12.7128-7135.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hopkins A. L., Ren J., Esnouf R. M., Willcox B. E., Jones E. Y., Ross C., Miyasaka T., Walker R. T., Tanaka H., Stammers D. K. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem. 1996 Apr 12;39(8):1589–1600. doi: 10.1021/jm960056x. [DOI] [PubMed] [Google Scholar]
  13. Kleim J. P., Bender R., Billhardt U. M., Meichsner C., Riess G., Rösner M., Winkler I., Paessens A. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother. 1993 Aug;37(8):1659–1664. doi: 10.1128/aac.37.8.1659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kleim J. P., Bender R., Kirsch R., Meichsner C., Paessens A., Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 1994 May 1;200(2):696–701. doi: 10.1006/viro.1994.1233. [DOI] [PubMed] [Google Scholar]
  15. Kleim J. P., Bender R., Kirsch R., Meichsner C., Paessens A., Rösner M., Rübsamen-Waigmann H., Kaiser R., Wichers M., Schneweis K. E. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 1995 Oct;39(10):2253–2257. doi: 10.1128/aac.39.10.2253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kleim J. P., Rösner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., Arnold E., Riess G. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):34–38. doi: 10.1073/pnas.93.1.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kleim J. P., Winkler I., Rösner M., Kirsch R., Rübsamen-Waigmann H., Paessens A., Riess G. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology. 1997 Apr 28;231(1):112–118. doi: 10.1006/viro.1997.8513. [DOI] [PubMed] [Google Scholar]
  18. Pérez-Pérez M. J., San-Félix A., Balzarini J., De Clercq E., Camarasa M. J. TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides. J Med Chem. 1992 Aug 7;35(16):2988–2995. doi: 10.1021/jm00094a009. [DOI] [PubMed] [Google Scholar]
  19. Schmit J. C., Cogniaux J., Hermans P., Van Vaeck C., Sprecher S., Van Remoortel B., Witvrouw M., Balzarini J., Desmyter J., De Clercq E. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis. 1996 Nov;174(5):962–968. doi: 10.1093/infdis/174.5.962. [DOI] [PubMed] [Google Scholar]
  20. Schmit J. C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., Vandamme A. M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS. 1996 Aug;10(9):995–999. doi: 10.1097/00002030-199610090-00010. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES